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Pancreatic --cell signaling: toward better understanding
of diabetes and its treatment
By Susumu SEINO,*1,*2,*3,† Tadao SHIBASAKI*1 and Kohtaro MINAMI*1
(Communicated by Hiroo IMURA, M.J.A.)
Abstract: Pancreatic --cells play a central role in the maintenance glucose homeostasis by
secreting insulin, a key hormone that regulates blood glucose levels. Dysfunction of the --cells and/
or a decrease in the --cell mass are associated closely with the pathogenesis and pathophysiology of
diabetes mellitus, a major metabolic disease that is rapidly increasing worldwide. Clariﬁcation of the
mechanisms of insulin secretion and --cell fate provides a basis for the understanding of diabetes
and its better treatment. In this review, we discuss cell signaling critical for the insulin secretory
function based on our recent studies.
Keywords: cell signaling, insulin, cAMP, Epac2, pancreatic acinar cell, transdiﬀerentiation
Introduction
The pancreatic --cell plays a central role in the
maintenance of glucose homeostasis by secreting
insulin, a key metabolic hormone that regulates
blood glucose levels. Dysfunction of the --cell
and/or a decrease in --cell mass are associated
closely with the pathogenesis and pathophysiology
of diabetes mellitus, a metabolic disease that has
come to aﬄict more than 250 million people in the
world at the present time and is still increasing in
prevalence globally.1) Studies of pancreatic --cells
provide a basis for understanding diabetes mellitus
and its better treatment as well as the regulation of
blood glucose levels. Current trends of pancreatic --
cell research include the mechanisms of the regulation
of insulin secretion by cell signaling, the mechanisms
of --cell fate, the roles of the --cell in the patho-
genesis and pathophysiology of diabetes mellitus, and
the development of novel therapies targeting the --
cell. In the past two decades, we have focused on the
following issues: 1) identiﬁcation of novel signaling
pathways (molecules) in the regulation of insulin
secretion, 2) the manner in which the intracellular
signals that regulate insulin secretion are spatially
and temporally integrated in --cells, 3) the mecha-
nism of acquisition of insulin secretory function in the
process of --cell diﬀerentiation, and 4) the relation-
ship between abnormalities in --cell signaling and the
development of diabetes. We are also endeavoring to
translate the information obtained by our basic
research into clinical practice. In this review, the cell
signaling critical for insulin secretory function will be
discussed by describing our recent studies on the
potentiation of insulin secretion by cAMP signaling
and the induction of insulin secreting-cells from
exocrine pancreas in vitro.
1. Potentiation of insulin secretion
by cAMP signaling
Stimulus–secretion coupling is a fundamental
biological event in the --cells.2),3) Ca2+, ATP, cAMP,
and phospholipid-derived signals such as inositol
1,4,5-triphosphate (IP3) and diacylglycerol (DAG)
are the major intracellular signals in insulin secretion
(Fig. 1). Glucose-stimulated insulin secretion (GSIS)
is the principal mechanism of insulin secretion.
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an increase in the ATP concentration (or ATP/ADP
ratio) due to increased glucose metabolism closes the
ATP-sensitive K+ (KATP) channels, depolarizing the
--cell membrane and opening the VDCCs, which
allows Ca2+ inﬂux. The resultant rise in [Ca2+]i in
the --cell triggers exocytosis of insulin granules.
Thus, KATP channels couple metabolic changes to
membrane potential.4) In addition to GSIS, signals
involved in the potentiation of GSIS are also
important for normal regulation of insulin secretion.
These include cAMP, DAG, and IP3, among which
cAMP is particularly important for amplifying GSIS.
cAMP is now known to have diverse actions in
insulin secretion. We have recently found that the
cAMP sensor cAMP-GEFII (Epac2) (referred to as
Epac2 hereafter)-mediated mechanism is required for
the action of sulfonylureas, widely used drugs in the
treatment of diabetes, as well as for the potentiation
of GSIS by cAMP in a protein kinase A (PKA)-
independent manner.
Modes of insulin granule exocytosis. Insulin
granule exocytosis includes several steps including
recruitment, docking, priming, and fusion to the
plasma membrane. Recently, investigation of insulin
granule exocytosis has been reﬁned by the use of the
total internal reﬂection ﬂuorescence microscopy
(TIRFM) system.5)–7) We monitored the dynamics
of insulin granule exocytosis from primary cultured
pancreatic --cells infected with adenovirus carrying
insulin fused with yellow ﬂuorescent protein
(Venus).6) Analyses by TIRFM in detail revealed
that the exocytotic process can be classiﬁed into three
modes based on the dynamics of the granules:
mode 1, in which predocked granules are immedi-
ately fused to the plasma membrane by stimulation
(named old face); mode 2, in which granules are
newly recruited by stimulation and immediately
fused (a docking state can hardly be detected by
TIRFM) to the plasma membrane (named restless
newcomer); and mode 3, in which granules are newly
recruited by stimulation, but are ﬁrst paused or
docked and then fused to the plasma membrane
(named resting newcomer)6) (Fig. 2A). We inves-
tigated to determine whether the diﬀerent modes of
insulin granule exocytosis might be caused by diﬀer-
ent stimuli. Fusion events induced by potassium
stimulation occur immediately upon stimulation with
potassium, and are transient. The majority of these
granules are old face. In contrast, fusion events
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Fig. 1. GSIS and its potentiation. Glucose is transported into the pancreatic --cell by the glucose transporter (GLUT). Metabolism of
glucose increases ATP production, closing the KATP channels, which results in membrane depolarization ("A), thus opening of
voltage-dependent calcium channels (VDCC) and allowing Ca2+ inﬂux. The resultant rise in [Ca2+]i triggers insulin secretion. Insulin
secretion is also modulated by hormones and neurotransmitters. Incretins such as GLP-1 and GIP bind to Gs-coupled receptors and
activate adenylyl cyclase (AC), which increases intracellular levels of cyclic AMP. cAMP activates both PKA and Epac2 to potentiate
insulin secretion. Achetylcholine (ACh), a major parasympathetic neurotransmitter, binds to Gq-coupled receptors and activates
phospholipase C- (PLC-). PLC- activation generates phospholipid-derived messengers. Among these, DAG activates PKC and IP3
mobilizes Ca2+ from intracellular storage sites.
S. SEINO,T .S HIBASAKI and K. MINAMI [Vol. 86, 564induced by glucose stimulation are biphasic: a ﬁrst
phase of acute increase and a second phase of
sustained increase. Interestingly, both phases of
fusion events induced by glucose stimulation involve
mostly restless newcomer. The existing model of
GSIS indicates that the ﬁrst phase of insulin secretion
results from the fusion of insulin granules from a
readily releasable pool (RRP) comprising predocked
granules (old face)8); the second phase results from
fusion of insulin granules from a reserve pool (RP)
comprising granules located farther away.9) Our data
suggest a new model of exocytosis in which both
phases are caused by newly recruited granules
(restless newcomer), some of which are from a
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Fig. 2. A. Modes of insulin granule exocytosis. There are three modes of insulin granule exocytosis, based on the dynamics of the
granules. Old face: predocked granules that are fused to the plasma membrane by stimulation. Restless newcomer: granules that are
newly recruited by stimulation and immediately fused to the plasma membrane. Resting newcomer: granules that are newly recruited
by stimulation, docked, and fused to the plasma membrane by stimulation. Sequential images (1µm × 1µm) acquired every 300msec
show these diﬀerent dynamics; the ﬂash indicates the fusion events. B. Models of GSIS. In the existing model of GSIS (Ref. 8), the ﬁrst
phase results from a readily releasable pool (RRP) comprising docked insulin granules (“old face” as deﬁned); the second phase results
from a reserve pool (RP) comprising granules located farther away (“resting newcomer” as deﬁned). In the new model, a RRP
responsible for the ﬁrst phase is located more than 50nm from the plasma membrane but is yet immediately releasable, and both the
ﬁrst and second phases of GSIS comprise restless newcomer. Blue, orange, and red indicates insulin granule exocytosis comprising old
face, resting newcomer, and restless newcomer, respectively.
Pancreatic --cell signaling No. 6] 565distance away from the plasma membrane yet are
readily releasable (Fig. 2B). In fact, we found that
the granule pool providing restless newcomer is likely
to be located more than 50nm from the plasma
membrane.10)
To ascertain which granule pools are involved
in glucose and potassium stimulation, --cells were
sequentially treated with the secretagogues under
two diﬀerent protocols.10) In one protocol, in which
the cells were stimulated with high potassium
(60mM) after glucose stimulation (16.7mM), the
fusion events occurred immediately and transiently,
and were caused mainly by old face, as was found in
the case of potassium stimulation alone without
initial glucose stimulation. In another protocol, in
which the cells were stimulated with glucose after
potassium stimulation, both the ﬁrst and second
phases of fusion events induced by glucose stimula-
tion were caused mostly by restless newcomer,
similar to the case in which the cells were stimulated
with glucose alone without initial potassium stim-
ulation. These ﬁndings indicate that potassium
stimulation and glucose stimulation induce fusion of
granules from distinct pools.
Importance of cAMP signaling in insulin
secretion. It is well known that oral administration
of glucose induces a greater insulin secretion than
a comparable glucose challenge given intrave-
nously.11),12) This is the so-called incretin eﬀect,
which refers to the potentiating action of gastro-
intestinal hormones on insulin secretion, including
GLP-1 (Glucagon-like peptide 1) and GIP (glucose-
dependent insulinotropic polypeptide, originally
called gastric inhibitory polypeptide).13),14) GLP-1
and GIP are released in response to the ingestion of
nutrients from gastrointestinal endocrine L-cells and
K-cells, respectively.15) Both of these hormones
potentiate GSIS16) by activation of cAMP signaling
in pancreatic --cells.17)–19) cAMP acts on insulin
secretion at various steps.20)–22) In normal pancreatic
islets, in vitro concentration-dependency of GSIS
displays a sigmoidal curve23) in which a glucose
concentration exceeding 6mmol/l is required for
triggering insulin secretion. On the other hand, a
study in man showed that GLP-1 infusion induced a
signiﬁcant increase in insulin secretion even at fasting
glucose levels of around 5.1mmol/l.24) In addition, it
has been reported that GLP-1 endows glucose-
insensitive --cells with glucose-competency, probably
by modulating KATP channel activity.25) These
ﬁndings suggest a mechanism by which cAMP may
induce glucose responsiveness of pancreatic --cells.
We recently found that treatment with GLP-1
induced glucose responsiveness in KATP channel-
deﬁcient (Kir6.2 null) mice in which there was almost
no insulin secretion in response to glucose,22) indicat-
ing that activation of cAMP signaling is important
for induction of glucose responsiveness in KATP
channel-deﬁcient --cells and that GLP-1 induces
GSIS by the KATP channel-independent mechanism.
GSIS is usually assessed by the insulin response
to a rapid and large increase in glucose concentration,
e.g., from 2.8mM to 16. 7mM in vitro. However, such
drastic change in glucose concentration is unlikely to
occur in vivo, in which blood glucose levels gradually
increase within a narrow range when glucose is taken
orally. To conﬁrm the importance of cAMP signaling
in GSIS under physiological conditions, we increased
the glucose concentration in a stepwise manner in the
presence or absence of cAMP in perfused pancreas.
Interestingly, these small and stepwise increases in
glucose concentration from 2.8mM to 11mM failed
to trigger insulin secretion in the absence of 8-Bromo-
cAMP or GLP-1, but dramatically evoked insulin
secretion in its presence. Such GSIS was almost
completely abolished by treatment with niﬂumic
acid. Considering that the blood glucose concentra-
tions increase gradually after meal ingestion from
4–5mmol/l to less than 8.0mmol/l26) with concom-
itant rises in incretin levels, pancreatic --cell cAMP
signaling activated by incretins may well play an
important role in maintaining the blood glucose
level within the physiological range. Thus, niﬂumic-
sensitive channels seem to be critically involved in
the mechanism of induction of GSIS by cAMP in the
physiological state.22)
Role of Epac2 (cAMP-GEFII)/Rap1 signal-
ing in insulin secretion. cAMP is a universal
intracellular second messenger involved in regulation
of various cellular functions in many cell types. It has
long been thought that cAMP regulates the potentia-
tion of insulin secretion through PKA phospho-
rylation of various proteins associated with the insulin
secretory process.2),27)–29) However, it is now known
that cAMP potentiates insulin granule exocytosis
by PKA-independent as well as PKA-dependent
mechanisms, the former involving the cAMP-binding
protein Epac2.30)–32) Epacs, Epac1 (also known as
cAMP-GEFI) and Epac2 (cAMP-GEFII), have so far
been identiﬁed.33)–35) Recently, a novel variant Epac2
lacking the N-terminal cAMP-binding domain of the
known Epac2 was found in mouse adrenal glands and
designated Epac2B (i.e. adrenal type); Epac2 is now
called Epac2A (brain/--cell type).36) A previously
S. SEINO,T .S HIBASAKI and K. MINAMI [Vol. 86, 566identiﬁed variant, which is speciﬁcally expressed in
liver, is referred to as Epac2C (liver type).37) Both
Epac1 and Epac2 proteins possess guanine nucleotide
exchange activity towards the small G-proteins
Rap1 and Rap2 in a cAMP-dependent manner.33)–35)
Structurally, both Epac proteins have common
features: a cAMP-binding domain and DEP
(Dishevelled, Egl-10, and Pleckstrin), REM (Ras
exchange motif), and GEF (guanine nucleotide
exchange factor) domains. Epac1 possesses one
cAMP-binding domain while Epac2 possesses two
cAMP-binding domains. Binding of cAMP to Epac2
is thought to cause conformational changes that
elicit GEF activity toward Rap proteins.38)
We previously showed that Epac2 mediates the
potentiation of cAMP-dependent, PKA-independent
insulin secretion.27),31),39) To clarify the role of Epac2
in insulin granule exocytosis directly, we examined
exocytosis in pancreatic --cells isolated from Epac2-
deﬁcient (Epac2 null) mice using the TIRFM
system.6) Although there was no diﬀerence in
glucose-induced exocytosis of insulin granules, we
found that potentiation by cAMP of the ﬁrst phase of
glucose-induced exocytosis was signiﬁcantly impaired
in Epac2 null mice.6) In addition, Rap1, which is
activated by cAMP speciﬁcally through Epac2 in
pancreatic --cells, was found to be required for PKA-
independent cAMP-potentiated insulin secretion.
Thus, Epac2/Rap1 signaling is important for the
potentiation by cAMP of the ﬁrst phase of GSIS. We
therefore propose that Epac2/Rap1 signaling regu-
lates cAMP-induced insulin granule exocytosis by
controlling the size of the RRP, most likely through
regulation of granule density6),10) (Fig. 3).
Epac2 as a novel target of antidiabetic
sulfonylurea drugs. K+ channels regulated by
intracellular ATP concentrations were ﬁrst reported
in guinea pig and rabbit cardiac cell membranes40)
and were later found in many cell types, including
pancreatic islet cells.4) KATP channels are critical in
the regulation of GSIS by coupling ATP, produced
by the metabolism of glucose, to electrical activity
of the --cell membrane, leading to calcium inﬂux
through opening of VDCCs. It was found that
tolbutamide, an antidiabetic drug, inhibits KATP
channels in pancreatic --cells, which suggested that
the channels are the target of sulfonylureas (SUs).41)
In 1995, the sulfonylurea receptor (now called SUR1)
from pancreatic --cell cDNA libraries was cloned
by Aguilar-Bryan et al.42) SUR1 is a member of the
ATP-binding cassette (ABC) protein superfamily.
We cloned Kir6.2,43) a member of the inwardly
rectifying K+ channel family, and established that
the --cell KATP channel is composed of Kir6.2 and
SUR1,43) which provided a basis of understanding of
KATP channels. Kir6.1 was cloned prior to Kir6.2.44)
The KATP channel is a hetero-octameric complex
comprising two subunits: a pore-forming subunit
Kir6.x (Kir6.1 or Kir6.2) and a regulatory subunit
SURx (SUR1, SUR2A, or SUR2B).45),46) Diﬀerent
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Fig. 3. Potentiation of insulin secretion by Epac2/Rap1 signaling. Activation of Epac2/Rap1 signaling promotes cAMP-induced, PKA-
independent insulin granule exocytosis by increasing the size of a readily releasable pool (RPP) near the plasma membrane. Epac2
includes cAMP-binding domain A and cAMP-binding domain B, DEP domain, REM, RA domain, and GEF.
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variant (mix and match) form KATP channels with
diﬀering nucleotide and SU sensitivities that play
distinct physiological and pathophysiological roles in
diﬀerent tissues.47) While Kir6.2 plus SUR1 consti-
tutes pancreatic --cell KATP channels, Kir6.2 plus
SUR2A constitutes cardiac and skeletal muscle KATP
channels. Kir6.2 plus SUR2B constitutes smooth
muscle KATP channels and Kir6.1 plus SUR2B
constitutes vascular smooth muscle KATP channels,
both of which are somewhat ATP-insensitive, nucleo-
tide diphosphate-activated, and glibenclamide-sensi-
tive K+ channels. It is now known that mutations of
KATP channels cause persistent hyperinsulinemic
hypoglycemia of infancy and neonatal diabetes,
depending on loss-of-function mutation or gain-of-
function mutation.48) KATP channels, as metabolic
sensors, play critical roles in various functions such as
insulin secretion, glucagon secretion,49) and protec-
tion against hypoxia-induced seizure50) and ischemic
heart.51)
Mice lacking KATP channels (Kir6.2 null mice
and SUR1 null mice) were generated.52),53) Neither
glucose nor tolbutamide stimulation elicited any
change in [Ca2+]i in Kir6.2 null --cells.52) Impor-
tantly, neither glucose nor tolbutamide stimulation
caused a signiﬁcant insulin secretion in Kir6.2 null
mice. The study of SUR1 null mice conﬁrmed also
that both glucose-induced and sulfonylurea-induced
insulin secretion depend critically on the activity of
--cell KATP channels.53) Based on these ﬁndings, it is
generally accepted that the primary target of SUs is
SUR1 and that action of SUs is mediated by closure
of the KATP channels through binding to SUR1.
In the course of our study of the Epac2-mediated
mechanisms of insulin secretion, we developed a
ﬂuorescence resonance energy transfer (FRET)-based
Epac2 sensor (termed C-Epac2-Y) in which the full-
length Epac2 is fused amino-terminally to enhanced
cyan ﬂuorescent protein (ECFP) and carboxyl-
terminally to enhanced yellow ﬂuorescent protein
(EYFP).54) Epac2 is a closed form in the inactive
state,32) so that ECFP and EYFP are located very
closely to each other (within 10nm), which causes
FRET. Upon cAMP binding to Epac2, Epac2
changes its conformation to an open form. As a
result, ECFP and EYFP separate away, so that
FRET does not occur (active state). Utilizing this
principle, we are able to monitor the activation status
of Epac2. In the search for agents that activate Epac2
using this FRET sensor, we found that tolbutamide,
glibenclamide, chlorpropamide, acetohexamide, and
glipizide signiﬁcantly decrease the FRET response in
COS-1 cells transfected with Epac2 FRET sensor, in
diﬀerent degrees and varying kinetics, suggesting
strongly that these SUs activate Epac2. However,
gliclazide, another SU, does not decrease the FRET
response. These ﬁndings indicate that the core
structure of sulfonylurea is required for binding to
Epac2. The fact that gliclazide, a sulfonylurea having
a side chain on the urea group larger than that of
other sulfonylureas, does not decrease FRET sug-
gests that the structure or size (or both) of the side
chain on the urea group determines the capability of
interaction between sulfonylureas and Epac2. Direct
binding of SU to Epac2 was conﬁrmed by speciﬁc
binding of radiolabeled glibenclamide to Epac2
expressed in COS-1 cells. Binding of [3H]glibencla-
mide to Epac2 was inhibited by unlabeled tolbuta-
mide or unlabeled glibenclamide in a concentration-
dependent manner, indicating that tolbutamide
binds speciﬁcally to Epac2 at the same binding site
as glibenclamide does. Speciﬁc binding of glibencla-
mide to Epac2 was not signiﬁcantly inhibited in the
presence of 8-Bromo-cAMP, suggesting that the
sulfonylurea-binding site is distinct from the cAMP-
binding sites.
We also found that tolbutamide and glibencla-
mide activate Rap1 in clonal pancreatic --cells
(MIN6 cells), but gliclazide does not. Interestingly,
although there was no diﬀerence in GSIS between
wild-type mice and Epac2 null mice, tolbutamide-
induced insulin secretion and glibenclamide-induced
insulin secretion from isolated pancreatic islets of
Epac2 null mice were signiﬁcantly reduced, compared
to those of wild-type mice. However, there was no
signiﬁcant diﬀerence in insulin secretion in response
to gliclazide between wild-type mice and Epac2 null
mice. Furthermore, the insulin response to oral
administration of tolbutamide alone or concomitant
administration of glucose and tolbutamide in Epac2
null mice was signiﬁcantly reduced, compared to that
in wild-type mice, and the glucose lowering eﬀect of
tolbutamide in Epac2 null mice was signiﬁcantly less
than that in wild-type mice.
As described above, it is well established that
SUs stimulate insulin secretion by eliciting a series of
ionic events including closure of KATP channels,
opening of VDCCs, and Ca2+ inﬂux into the --cells.
Although closure of the KATP channels is prerequisite
for SUs to stimulate insulin secretion, activation of
Epac2/Rap1 signaling is required for SUs to exert
their full eﬀects in insulin secretion. Considering the
role of Epac2/Rap1 signaling in insulin granule
S. SEINO,T .S HIBASAKI and K. MINAMI [Vol. 86, 568exocytosis described above, SUs may well increase
the size of a RRP of insulin granules near the plasma
membrane (Fig. 4).
2. Induction of insulin secreting-cells from
pancreatic exocrine cells in vitro
Although it has been reported that embryonic
stem (ES) cells can be manipulated to produce
insulin,55)–58) there are several obstacles to their
clinical use. Transplantation of ES cell derivatives
into human recipients can result in formation of ES
cell-derived tumors.59) Ethical problems also arise in
the acquisition of human ES cells.60) In addition, it
has been suggested that both the production and the
release of insulin in such manipulated ES cells may be
abnormal.61),62) On the other hand, recent studies
have shown that insulin-secreting cells can be
generated in vitro from adult non---cells including
mouse and human pancreatic duct cells,62)–65) rat
hepatic oval cells,66) and mouse bone marrow cells.67)
Although it was thought that terminally diﬀer-
entiated cells do not change their phenotype,
accumulating evidence suggests that phenotypic
plasticity is retained in diﬀerentiated cells. The most
intriguing example is induced-pluripotent stem (iPS)
cells, which have ES-cell like properties, generated
from somatic cells by introducing deﬁned factors.68)
Insulin-secreting cells have been generated from such
iPS cells.69) However, the use of iPS cells retains
problems similar to those involved in the use of ES
cells except for the ethical issues. On the other hand,
it has been shown that adult cells occasionally change
their phenotype without reprogramming into ES-like
pluripotent cells in chronic damage and tissue
regeneration, a phenomenon often called transdiﬀre-
nation.70) The pancreas is an organ in which
metaplasia, a pathological state involving trans-
diﬀerentiation,71),72) frequently occurs. For example,
hepatocyte-like cells appear in human pancreatic
cancer in some cases,73) and experimental conditions
such as copper depletion can lead to the development
of pancreatic hepatocytes in rodents.74),75) Since a
large number of pancreatic exocrine cells can be
obtained as a byproduct of islet transplantation,
the exocrine pancreas is a potential source for the
generation of transplantable surrogate --cells. In
vitro generation of insulin-positive cells from pancre-
atic exocrine cells has been reported by several
groups.76),77) However, neither direct evidence of the
origin of these cells nor their precise insulin secretory
properties was shown in those studies.
Generation of insulin-positive cells from
pancreatic exocrine cells. We have established a
method for the generation of insulin-secreting cells
from pancreatic exocrine cells in mice.78) The
pancreatic exocrine cell-enriched fraction was pre-
pared by Ficoll density gradient centrifugation. By
this method, pancreatic exocrine cells are recovered
as a pellet, and are then stained with dithizone, a
zinc-chelating agent, to remove contaminated pre-
existing pancreatic --cells. The resulting fraction
contains >90% of amylase-positive cells, approxi-
mately 5% of cytokeratin-positive cells, and less than
0.01% of insulin-positive cells. The exocrine cell-
enriched fractions were then cultured in RPMI-1640
medium supplemented with 0.5% fetal calf serum
(FCS) and 20ng/ml of EGF. Under these conditions,
the cells readily formed aggregates and became
smooth spheroids within a few days (Fig. 5). We
found that a subset of the cells in these colonies
expressed insulin. Most insulin-positive cells were
detected at the peripheral of small colonies. When the
isolated pancreatic exocrine cells were cultured in
suspension using dishes treated with 2-methacryloyl-
oxyethyl phosphorylcholine (MPC), which interferes
with cell attachment, insulin production was increas-
ed compared to that in monolayer culture. The
frequency of insulin-positive cells was increased to
³5% of total cells on day 4. The insulin-positive cells
also expressed C-peptide, indicating de novo biosyn-
thesis of insulin in these cells. Both amylase and
elastase, which are acinar cell-speciﬁc enzymes, were
strongly detected before culture (day 0) at both
mRNA (RT-PCR) and protein (immunoblotting)
levels. Immunocytochemistry showed that both
amylase- and elastase-positive cells comprised more
than 90% of total cells in the initial preparation (day
0), but less than 5% 4 days after culture. While CK
(ductal marker)-positive cells were rare at day 0, CK-
positive ductal structures were found frequently at
day 4 and day 6. Although insulin-positive cells were
generally negative for amylase, a few cells clearly
expressed both insulin and amylase, suggesting that
the insulin-producing cells in the culture are derived
from amylase/elastase-expressing mature pancreatic
acinar cells.78)
Origin of the newly made insulin-positive
cells. To identify the origin of the newly-made
insulin-producing cells, we utilized the method of cell
lineage tracing. In this method, ROSA26-loxP-stop-
loxP-ECFP reporter mouse (R26R-ECFP)-express-
ing ECFP that can be activated through the action of
Cre recombinase79) and adenoviruses in which either
amylase-2 (Ad-pAmy-Cre) or elastase-1 (Ad-pEla-
Pancreatic --cell signaling No. 6] 569Cre) promoter that drives the expression of Cre
recombinase are used. Pancreatic exocrine cells from
R26R-ECFP mice were infected with these adenovi-
ruses to label pancreatic acinar cells, and cultured as
described. After the culture, ECFP-expressing in-
sulin-positive cells were frequently found, demon-
strating that the insulin-positive cells originate from
amylase-expressing pancreatic acinar cells.78) We also
found that glucagon-positive cells, somatostatin-
positive cells, and a subset of CK-positive cells in
the culture also originate from the acinar cells.80)
Accordingly, pancreatic acinar cells possess plasticity
to convert into both endocrine and ductal cells.
Properties of the newly made cells. Glucose
transporters, glucokinase, KATP channels, VDCCs,
molecules associated with the exocytotic machinery
(SNAREs), and prohormone convertases (PC1/3
and PC2) are required for proper GSIS. The
expressions of all of these molecules were induced or
up-regulated in pancreatic acinar cells after the
culture. The expression proﬁles of the exocrine
pancreas-derived insulin-producing cells became sim-
ilar to those of pancreatic islets. In addition,
formation of insulin-containing granules was con-
ﬁrmed by immunoelectron microscopy, indicating
that these cells can secrete insulin in a regulated
manner. Indeed, KCl at a high concentration
stimulated insulin secretion from the pancreatic
acinar-derived cells, indicating the occurrence of
Ca2+-triggered exocytosis. Insulin secretion also was
increased by glibenclamide, a sulfonylurea commonly
used in treatment of diabetes, indicating that func-
tional KATP channels are expressed. Importantly,
GSIS from exocrine pancreas-derived cells was
detected in a concentration-dependent manner,
indicating that the cells are glucose responsive. In
addition, GLP-1 (7-36 amide), an incretin, potenti-
ated insulin secretion in the presence of relatively
high concentrations of glucose, indicating that
the cAMP-mediated potentiation system also is
present in the cells (Fig. 6). These results show that
pancreatic acinar-derived cells have qualitatively
similar insulin secretory properties to those of native
pancreatic --cells. However, insulin content in these
KATP channel
Epac2
SUR1
Rap1
Sulfonylurea
Ca2+
VDCC
Ca2+
Kir6.2
RRP
∆Ψ
Insulin granule exocytosis
Fig. 4. Model of sulfonylurea stimulation of insulin secretion. SUs close KATP channels by binding to SUR1, which leads to calcium inﬂux
by opening of VDCCs. SUs also bind Epac2 to activate Rap1 signaling, which increases the size of a RRP of insulin granules near the
plasma membrane.
100 µm 20 µm
Insulin/DAPI
AB
Fig. 5. Spheroids formed by pancreatic acinar cell culture. A.
The pancreatic acinar cells form spherical cell clusters within a
few days by culture with EGF. B. Insulin-positive cells are
shown in culture.
S. SEINO,T .S HIBASAKI and K. MINAMI [Vol. 86, 570pancreatic acinar-derived cells (including both
insulin-positive and insulin-negative cells) is only
1/400 that of native pancreatic islets. Since the
frequency of insulin-positive cells is approximately
5% of total cells in the culture, the insulin content of
the newly made insulin-positive cells is about 1/20
that of a native --cell78) on a cell to cell basis.
Dediﬀerentiation and rediﬀerentiation proc-
esses in induction of the insulin-secreting cells.
During development of the pancreas, several tran-
scription factors are known to play critical roles in --
cell diﬀerentiation. Pdx1, a transcription factor seen
early in the developing pancreas and restricted to --
cells in adults, was induced in pancreatic acinar-
derived cells by the culture at both mRNA and
protein levels. Other transcription factors character-
istic of endocrine pancreas (NeuroD1, Isl1, Pax6,
Nkx2.2, Nkx6.1, Hlxb9, HNF1a, and Foxa1) also
were induced. Foxa2 is expressed in early endo-
derm81) and all pancreatic cell types including
endocrine and exocrine cells in adult.82) Although
we could not detect Foxa2 expression in isolated
acinar cells, probably due to the low expression level,
Foxa2 was induced at both mRNA and protein levels
after the culture. HNF6, which is required for the
expression of Foxa2,83) also was induced. Ptf1a
expression was increased by the culture. Although
Ptf1a was thought to be an exocrine-speciﬁc tran-
scription factor,84) a recent study has shown that this
factor also is expressed in the pancreatic bud and is
required for diﬀerentiation into all three cell types
(endocrine, exocrine, and duct) of the pancreas.85)
These results suggest that pancreatic acinar cells
dediﬀerentiate into cells having the properties of
endocrine progenitors.
Cell signaling required for induction of
insulin-secreting cells from pancreatic acinar cells
in vitro. We found that enzymatic dissociation of
the pancreas leads to activation of the EGF receptor
and its downstream signaling. The EGF receptor was
not activated before dissociation but was activated
(tyrosine phosphrylated) by enzymatic dissociation.
When an inhibitor of EGF receptor kinase (AG1478)
was applied, transdiﬀerentiation of isolated pancre-
atic acinar cells into insulin-secreting cells was
inhibited,78) demonstrating that activation of the
EGF receptor is essential for the transdiﬀerentiation.
In embryonic pancreas, EGF increases the number
of undiﬀerentiated endocrine precursor cells, and,
upon removal of EGF, a large number of --cells are
diﬀerentiated,86) suggesting that EGF may be im-
portant for the proliferation of endocrine precursors
and/or endow the cells with commitment to endo-
crine lineage. We have found that activation of the
PI3-kinase pathway is critical for the transdiﬀeren-
tiation of pancreatic acinar cells into insulin-secreting
cells and have shown that isolated pancreatic
acinar cells form spheroids (3-D structures) when
cultured in the presence of EGF.87) In the presence of
a PI3-kinase inhibitor, LY294002, the formation of
spheroids was blocked and induction of the genes
characteristic of pancreatic --cells was signiﬁcantly
suppressed, demonstrating that PI3-kinase is essen-
tial for the transdiﬀerentiation of pancreatic acinar
cells into insulin-secreting cells. These results suggest
that cell–cell interaction is involved in the process.
Although cadherin-mediated cell–cell adhesions were
disrupted by enzymatic dissociation of pancreatic
acinar cells, they were recovered by culture with
EGF. Since cell-to-cell contact is known to play
important roles in fate determination of many cell
types, the impacts of inhibition of cell-to-cell contact
on such transdiﬀerentiation were investigated using a
neutralizing antibody against E-cadherin (ECCD-1).
When spheroid formation in isolated acinar cells was
inhibited by addition of the antibody, inductions of
genes speciﬁc for pancreatic --cells were signiﬁcantly
suppressed, while transcription factors seen early in
pancreas development such as HNF6 and Foxa2 were
still up-regulated87) (Fig. 7). Activation of PI3-kinase
resulted in up-regulation of both E-cadeherin and --
catenin, major components of cadherin-mediated
cell–cell adhesion, and blocked degradation of these
proteins, which leads to the recovery of the adhesion.
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Fig. 6. Insulin secretion from transdiﬀerentiated pancreatic
acinar cells. Insulin secretion is stimulated by glucose and
enhanced by glucagon-like peptide-1 (GLP-1) (7–36 amide)
(100nM).
Pancreatic --cell signaling No. 6] 571It has been reported that acinar-to-- cell trans-
diﬀerentiation is not found in vivo.88) This is
probably because loss of cell adhesion of pancreatic
acini rarely occurs in vivo.
Model of the mechanism of induction of
insulin-secreting cells from pancreatic acinar cells
in vitro. A model of pancreatic acinar-to-- cell
transdiﬀerentiation is depicted in Fig. 8: enzymatic
dissociation of exocrine pancreas disrupts the epi-
thelial structures of acini, including cadherin-medi-
ated cell–cell adhesion, which causes dediﬀerentiation
of the acinar cells. Spontaneous activation of the
EGF receptor and its downstream signals occurs
after isolation of the cells, and the addition of EGF
enhances these signals. Remodeling of cell–cell
interaction by restored cadherin-mediated cell–cell
adhesion, which is promoted by activation of the
PI3-kinase pathway, induces rediﬀerentiation of the
dediﬀerentiated pancreatic acinar cells into insulin-
secreting cells. Thus, loss and restoration of PI3-
kinase-dependent cadherin-mediated cell–cell adhe-
sion is essential for induction of insulin-secreting cells
from pancreatic acinar cells in vitro.
Coda
Although the discovery of insulin in 1921 by
Banting and Best brought the ﬁrst and foremost good
news to patients with diabetes mellitus, how the
pancreatic --cell produces and secretes insulin and
how the --cell is generated and maintained are still
puzzling questions. Normal pancreatic --cells are
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Fig. 8. Model for pancreatic acinar-to-- cell transdiﬀerentiation. Enzymatic dissociation disrupts epithelial structures of acini, resulting
in loss of cadherin-mediated cell–cell adhesion, which causes dediﬀerentiation of the acinar cells. Meanwhile, EGF receptors are
activated, which is followed by activation of the PI3-kinase pathway. Within a few days of culture, cadherin-mediated cell–cell
adhesion is recovered by the enhanced expression of E-cadherin, which is essential for rediﬀerentiation of the dediﬀerentiated cells into
insulin-secreting cells.
S. SEINO,T .S HIBASAKI and K. MINAMI [Vol. 86, 572equipped with a very precise apparatus that allows
adjustment of insulin secretion in response to mo-
ment-to-moment changes in blood glucose levels, and
thus precisely maintain blood glucose levels within
the narrow physiological range that protects the
various organs from the development of the many
serious diabetic complications. In addition to insulin,
various antidiabetic drugs targeting --cells have
been developed to treat diabetes. Understanding
the signaling mechanisms of insulin secretion and
those of the generation of --cells should provide clues
for development of novel therapeutic strategies as
well as understanding the signaling mechanisms of
insulin secretion and those of the generation of --cells
should provide clues for development of novel
therapeutic strategies as well as clariﬁcation of the
pathogenesis and pathophysiology of diabetes.
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